Novo Nordisk filed suit against telehealth company Hims & Hers alleging infringement of semaglutide (Wegovy) patents, and signaled it may seek 'hundreds of millions' in damages. The complaint targets both pill and injectable formulations, according to Novo Nordisk's announcement. Days after Novo’s legal action and regulatory scrutiny, Hims said it would stop offering a compounded GLP‑1 pill version of Wegovy following FDA backlash and legal threats. Hims’ withdrawal came amid overlapping patent, regulatory and enforcement pressures that crystallized quickly. The dispute highlights tensions between originator biopharma protecting complex‑molecule patents and telehealth/compounding strategies attempting to broaden access to branded GLP‑1 effects.